Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...

Leerink Partners served as exclusive financial advisor to Banner and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor. To find out more about BAFIERTAM, please visit www.bafiertam.com.

Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

They issued an “outperform” rating and a $11.00 price objective on the stock. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday ...

Align Technology upgraded to Outperform with a $280 price target by Leerink Partners. Q3 adjusted EPS beats at $2.35, while sales rose 1.8% to $977.9 million. Get Pro-Level Earnings Insights ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...